Frontlight ResearchEarly access
Taking people in United StatesPhase 1/2
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
Key facts
- Who runs it
- Case Comprehensive Cancer Center
- Where
- Cleveland, United StatesSee the 2 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 36 people, planned
- Started
- 3 Jul 2013
- Expected to end
- Sept 2027
- Type of study
- Interventional
- Treatments tested
- radiosurgery
- therapeutic conventional surgery
- quality-of-life assessment
- Record updated
- 9 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Have a prior histologic diagnosis of cancer other than small cell lung cancer, lymphoma, and germ cell histologies
- Magnetic resonance imaging (MRI) evidence of 1-4 brain metastases, with at least one lesion > 20 mm and ≤ 50 mm in maximal diameter and determined to be appropriate for SRS and gross total resection; all other brain metastases are appropriate for SRS
- Patient can have prior SRS to lesions other than the one planned for neoadjuvant SRS and resection
- Patient must have a Karnofsky performance score of ≥ 70
Who cannot take part
- Patient deemed medically unfit to undergo surgical resection of brain metastasis
- Prior whole brain radiotherapy
- Imaging or cytologic evidence of leptomeningeal disease
- Patient with contraindication for imaging with MRI
- Inability to participate in study activities due to physical or mental limitations
- Inability or unwillingness to return for all the required follow-up visits
- At the time of planning, unable to deliver 10 Gray (Gy) or less to optic nerve/chiasm
- Tumor located in the brainstem
Where in United States
- Cleveland Clinic, Case Comprehensive Cancer CenterCleveland, United StatesContact: Erin Murphy, MDTaking people
- University Hospitals Cleveland Medical Center, Case Comprehensive Cancer CenterCleveland, United StatesContact: Erin Murphy, MDNo longer taking part
About the trial
What the trial wants to find out
This Phase I/II trial studies the ability to stop brain metastases from coming back after treatment with radiosurgery followed by surgical resection. It will also evaluate the side effects of these combined treatments and help determine the best radiosurgery dose. Radiosurgery focuses the x-rays directly to the tumor and cause less damage to the normal tissue in the brain.
The group in the trial
- Treatment (radiosurgery, surgery)Treatment being tested
Patients undergo radiosurgery on day 0. Within 2 weeks, patients undergo surgical resection.
Treatment: radiosurgery, therapeutic conventional surgery, and quality-of-life assessment
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 9 October 2026